SAN
DIEGO, March 9, 2023 /PRNewswire/ -- Evofem
Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the
appointment of Albert Altro as
Interim Chief Financial Officer of the Company. He replaces
Jay File, who is leaving the Company
to explore other opportunities.
Mr. Altro brings over 25 years of financial and operational
experience including corporate restructuring, public accounting and
executive management, and consulting, primarily in a leadership
role. His experience spans a variety of industries and
organizations, servicing primarily middle market privately held
corporations, as well as debtors-in-possession, secured and
unsecured creditors, private equity groups and strategic buyers.
Prior to forming Traverse LLC in 2005, Mr. Altro worked at KPMG in
both the auditing group and the strategic consulting practice; he
also was a Director at PricewaterhouseCoopers in the Transaction
Services Group and worked as a corporate restructuring advisor at
Zolfo Cooper (acquired by Alix Partners).
"We will look to Albert's extensive experience to inform
and direct our fiscal strategy as we explore options to build
shareholder value," said Saundra
Pelletier, Chief Executive Officer of Evofem.
Mr. Altro has served on the boards of directors of The Corporate
Presence, Pekay Boutiques, Bumblebee Foods and Paramount Business
Solutions. He holds a BA in accounting from Long Beach State, and
is a member of the Association of Insolvency and Restructuring
Advisors (AIRA) and the Turnaround Management
Association (TMA).
Pelletier added, "On behalf of the Board I want to thank Jay for
his services and wish him success in his future endeavors."
About Evofem
Evofem Biosciences,
Inc., is developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health. The
Company's first FDA-approved
product, Phexxi® (lactic acid, citric acid
and potassium bitartrate), is a hormone-free,
on-demand prescription contraceptive vaginal gel. It comes in a box
of 12 pre-filled applicators and is applied 0-60 minutes before
each act of sex. Learn more
at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Forward-Looking Statements
This press release includes
"forward-looking statements," within the meaning of the safe harbor
for forward-looking statements provided by Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995 including, without
limitation, statements related to Mr. Altro's expected
contributions to Evofem. You are cautioned not to place undue
reliance on these forward-looking statements, which are current
only as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties.
Important factors that could cause actual results to differ
materially from those discussed or implied in the forward-looking
statements are disclosed in the Company's SEC filings, including
its Annual Report on Form 10-K for the year ended December 31,
2021, filed with the SEC on March 10, 2022, its Quarterly
Report on Form 10-Q for the quarter ended September 30,
2022 filed with the SEC on January 6, 2023 and any
subsequent filings. All forward-looking statements are expressly
qualified in their entirety by such factors. The Company does not
undertake any duty to update any forward-looking statement except
as required by law.
Contacts
Evofem Biosciences,
Inc.
Amy Raskopf
SVP, Investor Relations
araskopf@evofem.com / media@evofem.com
(917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-appoints-interim-chief-financial-officer-301767432.html
SOURCE Evofem Biosciences, Inc.
